ChauTDangMD

Assistant Professor, Medicine, Weill Cornell Medical College

Overview of Dr. Dang

Dr. Chau Dang is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, NYC Health + Hospitals / Bellevue, Phelps Memorial Hospital Center, and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from Medical University of South Carolina College of Medicine and has been in practice 25 years. Dr. Dang accepts several types of health insurance, listed below. She is one of 464 doctors at Memorial Sloan Kettering Cancer Center and one of 61 doctors at NYC Health + Hospitals / Bellevue who specialize in Oncology. She has more than 100 publications and over 500 citings.

Office
Memorial Sloan Kettering Cancer Center Westchester
500 Westchester Avenue
New York, NY 10021
Book by Phone+1(773) 569-3576
Is this information wrong?

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1996 - 1999
Allegheny Health Network Medical Education Consortium (AGH)Residency, Internal Medicine, 1993 - 1996
Eastern Virginia Medical SchoolInternship, Transitional Year, 1992 - 1993
Medical University of South CarolinaClass of 1992

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2019 - 2025
NY State Medical License 1996 - 2025
PA State Medical License 1994 - 1996

Clinical Trials

Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer Start of enrollment: 2000 Jun 01
Completed
Phase 2
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer Start of enrollment: 2007 Nov 02
Active, not recruiting
Phase 3
Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer Start of enrollment: 2007 Mar 01
Completed
Phase 2
Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility Start of enrollment: 2004 Dec 01
Completed
Phase 2
Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility Start of enrollment: 2004 Nov 01
Completed
Not Applicable
Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer Start of enrollment: 2011 Jan 05
Completed
Phase 2
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Start of enrollment: 2012 Dec 11
Completed
Phase 2
Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 2
Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy Start of enrollment: 2015 Jan 12
Active, not recruiting
Phase 2
Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer Start of enrollment: 2017 Dec 13
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collabo...
Veerle Bossuyt, Elena Provenzano, W Fraser Symmans, Fleur Webster, Kimberly H Allison, Chau Dang, Gobbi Helenice, Janina Kulka, Sunil R Lakhani, Takuya Moriya, Cecily ...> ;Histopathology. 2024 Mar 5
Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]).
Geyer, C., Blum, J., Yothers, G., Asmar, L., Flynn, P., Robert, N., Hopkins, J., O'Shaughnessy, J., Rastogi, P., Puhalla, S., Hilton, C., Dang, C., Gómez, H., Vukelja,...> ;Journal of Clinical Oncology. 2024 Feb 9
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients.
Stephanie Gu, Stephen Dusza, Elizabeth Quigley, Helen Haliasos, Alina Markova, Michael Marchetti, Andrea P Moy, Chau Dang, Shanu Modi, Diana Lake, Sarah Noor, Mario E ...> ;Breast Cancer Research and Treatment. 2024 Jan 1
Nomogram for Predicting Risk of Cancer Therapy-Related Cardiac Dysfunction in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Anthony F Yu, I-Hsin Lin, Justine Jorgensen, Robert Copeland-Halperin, Stephanie Feldman, Amare Assefa, Michelle N Johnson, Chau T Dang, Jennifer E Liu, Richard M Stei...> ;Journal of the American Heart Association. 2023 Oct 3
1 citations
Association of Circulating Cardiomyocyte Cell-Free DNA With Cancer Therapy-Related Cardiac Dysfunction in Patients Undergoing Treatment for ERBB2-Positive Breast Cancer.
Anthony F Yu, Zachary R Moore, Chaya S Moskowitz, Jennifer E Liu, Chau T Dang, Lakshmi Ramanathan, Kevin C Oeffinger, Richard M Steingart, Adam M Schmitt> ;JAMA Cardiology. 2023 Jul 1
Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Comparative Effectiven...
Letizia Polito, Jinjoo Shim, Sara A Hurvitz, Chau T Dang, Adam Knott, Yolande Du Toit, Eleonora Restuccia, Thibaut Sanglier, Sandra M Swain> ;JCO Oncology Practice. 2023 Jul 1
2 citations
Cytochrome P450 Oxidoreductase (POR) Associated with Severe Paclitaxel-Induced Peripheral Neuropathy in Patients of European Ancestry from ECOG-ACRIN E5103.
Fei Shen, Guanglong Jiang, Santosh Philips, Laura Gardner, Gloria Xue, Erica Cantor, Reynold C Ly, Wilberforce Osei, Xi Wu, Chau Dang, Donald Northfelt, Todd Skaar, Ka...> ;Clinical Cancer Research. 2023 Jul 5
Pruritus Related to Trastuzumab and Pertuzumab in HER2+ Breast Cancer Patients.
Stephanie Gu, Stephen Dusza, Elizabeth Quigley, Helen Haliasos, Alina Markova, Michael Marchetti, Andrea Moy, Chau Dang, Shanu Modi, Diana Lake, Sarah Noor, Mario Laco...> ;Research Square. 2023 Apr 28
1 citations
Rationale and design of a cardiac safety study for reduced cardiotoxicity surveillance during HER2-targeted therapy.
Anthony F Yu, Chau T Dang, Justine Jorgensen, Chaya S Moskowitz, Patricia DeFusco, Eric Oligino, Kevin C Oeffinger, Jennifer E Liu, Richard M Steingart> ;Cardio-Oncology. 2023 Mar 9
3 citations
Innate immune signaling drives late cardiac toxicity following DNA-damaging cancer therapies.
Achraf Shamseddine, Suchit H Patel, Valery Chavez, Zachary R Moore, Mutayyaba Adnan, Melody Di Bona, Jun Li, Chau T Dang, Lakshmi V Ramanathan, Kevin C Oeffinger, Jenn...> ;The Journal of Experimental Medicine. 2023 Mar 6
35 citations
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Tolaney, S., Tarantino, P., Graham, N., Tayob, N., Parè, L., Villacampa, G., Dang, C., Yardley, D., Moy, B., Marcom, P., Albain, K., Rugo, H., Ellis, M., Shapira, I., ...> ;The Lancet. Oncology. 2023 Mar 1
7 citations
Timing of exercise therapy when initiating adjuvant chemotherapy for breast cancer: a randomized trial.
Jessica M Scott, Jasme Lee, James E Herndon, Meghan G Michalski, Catherine P Lee, Kelly A O'Brien, John P Sasso, Anthony F Yu, Kylie A Rowed, Jacqueline F Bromberg, Ti...> ;European Heart Journal. 2023 Dec 7
1 citations
Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer.
Mark Pegram, Richard Pietras, Chau T Dang, Rashmi Murthy, Thomas Bachelot, Wolfgang Janni, Priyanka Sharma, Erika Hamilton, Cristina Saura> ;Therapeutic Advances in Medical Oncology. 2023 Jan 1
4 citations
Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT).
Tal Sella, Yue Zheng, Nabihah Tayob, Kathryn J Ruddy, Rachel A Freedman, Chau Dang, Denise Yardley, Steven J Isakoff, Vicente Valero, Michelle DeMeo, Harold J Burstein...> ;NPJ Breast Cancer. 2022 Nov 30
10 citations
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis.
Sandra M Swain, Harrison Macharia, Javier Cortes, Chau Dang, Luca Gianni, Sara A Hurvitz, Christian Jackisch, Andreas Schneeweiss, Dennis Slamon, Pinuccia Valagussa, Y...> ;Cancers. 2022 Oct 15
1 citations
Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuz...
Sandra M Swain, Antoinette R Tan, Luca Gianni, Sherko Kuemmel, Chau T Dang, Andreas Schneeweiss, Joyce O'Shaughnessy, Haiying Liu, Christian Aguila, Sarah Heeson, Harr...> ;European Journal of Cancer. 2023 Jan 1
ASO Visual Abstract: Neoadjuvant Chemotherapy for Breast Cancer in the Elderly-Are We Accomplishing Our Treatment Goals?
Austin D Williams, Chau T Dang, Varadan Sevilimedu, Monica Morrow, Andrea V Barrio> ;Annals of Surgical Oncology. 2022 Dec 1
3 citations
Neoadjuvant Chemotherapy for Breast Cancer In the Elderly: Are We Accomplishing Our Treatment Goals?
Austin D Williams, Chau T Dang, Varadan Sevilimedu, Monica Morrow, Andrea V Barrio> ;Annals of Surgical Oncology. 2022 Dec 1
7 citations
Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review.
Edith A Perez, Chau Dang, Caleb Lee, Jasmeet Singh, Kongming Wang, J Bradley Layton, Alicia Gilsenan, Michelle D Hackshaw, Javier Cortes> ;Breast Cancer Research and Treatment. 2022 Jul 1
293 citations
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Elias, A., Savur Moran, M. S., William J Gradishar, Meena S Moran, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H Allison, Bethany Anderson, Harold J Burstein, H...> ;Journal of the National Comprehensive Cancer Network. 2022 Jun 1
7 citations
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive...
Chau Dang, Michael S Ewer, Suzette Delaloge, Jean-Marc Ferrero, Ramon Colomer, Luis de la Cruz-Merino, Theresa L Werner, Katherine Dadswell, Mark Verrill, Daniel Eiger...> ;Cancers. 2022 May 24
8 citations
Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination W...
Jennifer R Bellon, Nabihah Tayob, David D Yang, Jordan Tralins, Chau T Dang, Steven J Isakoff, Michelle DeMeo, Harold J Burstein, Ann H Partridge, Eric P Winer, Ian E ...> ;International Journal of Radiation Oncology, Biology, Physics. 2022 May 1
7 citations
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab.
Emanuela Ferraro, Jasmeet Singh, Sujata Patil, Pedram Razavi, Shanu Modi, Sarat Chandarlapaty, Andrea V Barrio, Rachna Malani, Ingo K Mellinghoff, Adrienne Boire, Hann...> ;NPJ Breast Cancer. 2022 Mar 22
8 citations
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TB...
Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, Chau Dang, Denise A Yardley, Steven J Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Jiani...> ;NPJ Breast Cancer. 2022 Feb 16
10 citations
Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer.
Joseph A Sparano, Anne O'Neill, Noah Graham, Donald W Northfelt, Chau T Dang, Antonio C Wolff, George W Sledge, Kathy D Miller> ;NPJ Breast Cancer. 2022 Feb 8
Join now to see all

Journal Articles

Left Ventricular Ejection Fraction Monitoring Adherence Rates
Chau T Dang, Sandra M Swain, Anne Blaes, ScienceDirect

Press Mentions

Impressive Disease Control in Metastatic Triple-Negative Breast CancerMay 14th, 2021
Emerging Cardio-Oncology Field Fights Heart Disease in Breast Cancer PatientsOctober 30th, 2019
PCI in Cancer; Beta-Blocker Prophylaxis; Stress Echo Predicts Cancer DeathsDecember 10th, 2018
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

Memorial Sloan Kettering Cancer CenterNew York, New York
NYC Health + Hospitals / BellevueNew York, New York
Phelps Memorial Hospital CenterTarrytown, New York
Memorial Hospital for Cancer and allied DiseasesBasking Ridge, New Jersey

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment